Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients

BMJ Open Respir Res. 2019 Sep 24;6(1):e000440. doi: 10.1136/bmjresp-2019-000440. eCollection 2019.

Abstract

Background: Pleural infection (PI) is a major global disease with an increasing incidence, and pleural fluid (PF) drainage is essential for the successful treatment. The MIST2 study demonstrated that intrapleural administration of tissue plasminogen activator (t-PA) and DNase, or t-PA alone increased the volume of drained PF. Mouse model studies have suggested that the volume increase is due to the interaction of the pleura with the t-PA via the monocyte chemoattractant protein 1 (MCP-1) pathway. We designed a study to determine the time frame of drained PF volume induction on intrapleural delivery of t-PA±DNase in humans, and to test the hypothesis that the induction is mediated by the MCP-1 pathway.

Methods: Data and samples from the MIST2 study were used (210 PI patients randomised to receive for 3 days either: t-PA and DNase, t-PA and placebo, DNase and placebo or double placebo). PF MCP-1 levels were measured by ELISA. One-way and two-way analysis of variance (ANOVA) with Tukey's post hoc tests were used to estimate statistical significance. Pearson's correlation coefficient was used to assess linear correlation.

Results: Intrapleural administration of t-PA±DNase stimulated a statistically significant rise in the volume of drained PF during the treatment period (days 1-3). No significant difference was detected between any groups during the post-treatment period (days 5-7). Intrapleural administration of t-PA increased MCP-1 PF levels during treatment; however, no statistically significant difference was detected between patients who received t-PA and those who did not. PF MCP-1 expression was not correlated to the drug given nor the volume of drained PF.

Conclusions: We conclude that the PF volume drainage increment seen with the administration of t-PA does not appear to act solely via activation of the MCP-1 pathway.

Keywords: DNase; empyema; fibrinolytics; pleural infection; t-PA.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemokine CCL2 / analysis
  • Deoxyribonucleases / administration & dosage*
  • Drainage*
  • Empyema, Pleural / therapy*
  • Humans
  • Pleura
  • Pleural Effusion / therapy*
  • Tissue Plasminogen Activator / administration & dosage*

Substances

  • Chemokine CCL2
  • Deoxyribonucleases
  • Tissue Plasminogen Activator